B
Bull
Bull · 25%TRAW
$1.17
Szenariopreis
$0.590
+0.005 (+0.77%)Zum Schluss
Loading chart…
- High
- 0.600
- Open
- 0.600
- VWAP
- 0.59
- Vol
- 43.98K
- Mkt Cap
- —
- Low
- 0.580
- Amount
- 25.94K
- EV/EBITDA, TTM
- 0.00
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
AI analysis of Traws Pharma Inc (TRAW)
buyTraws Pharma Inc appears to be a good buy right now, trading at $0.5899 with a recent RSI of 63.926, indicating bullish momentum. The stock has shown a 5-day change of +11.30% and a 20-day change of +31.09%, suggesting positive short-term performance. However, the main risk is the recent downgrade by analysts, particularly due to the delay in the flu drug study, which has led to a significant drop in market confidence.
Bewertungskennzahlen
The current forward P/E ratio for Traws Pharma Inc (TRAW) is 0.00, compared to its 5-year average forward P/E of -1.20.
Alphio AI Price Scenarios for TRAW
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-14NewsfilterTraws Pharma Advances Tivoxavir Marboxil for MHRA Resubmission
9.006-13stocktwitsTraws Pharma Delays Key Study for Flu Drug
- 9.006-12Newsfilter
Traws Pharma Defers Influenza Drug Trial Due to Regulatory Review
9.505-15seekingalphaTraws Pharma Q1 Earnings Beat Expectations
2.005-08Yahoo FinanceHealthcare Stocks Decline Late Friday Afternoon
TRAW FAQ — answered by Alphio AI
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology. It operates in the Healthcare sector.
Traws Pharma Inc appears to be a good buy right now, trading at $0.5899 with a recent RSI of 63.926, indicating bullish momentum. The stock has shown a 5-day change of +11.30% and a 20-day change of +31.09%, suggesting positive short-term performance. However, the main risk is the recent downgrade by analysts, particularly due to the delay in the flu drug study, which has led to a significant drop in market confidence.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.